<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324297</url>
  </required_header>
  <id_info>
    <org_study_id>CDHA-RS_2011-215</org_study_id>
    <nct_id>NCT01324297</nct_id>
  </id_info>
  <brief_title>The Topical Niacin Skin Flush Test in First Episode Psychosis</brief_title>
  <official_title>The Topical Niacin Skin Flush Test: A Means for Longitudinal Monitoring of Two Different Biological Subgroups of Patients With First Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather normative data from healthy adults and to determine a
      sensitive and specific cut-off value for responders and non-responders to the Niacin Skin
      Flush Test in a sample of first episode psychosis patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to secure funding for second phase of study (i.e., niacin skin flush test in early
    psychosis patients).
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in visual rating of skin response (redness and oedema)</measure>
    <time_frame>ratings made at 3, 6, 9 and 12 minutes after application of methyl nicotinate</time_frame>
    <description>A 7-point visual rating scale, previously tested for reliability (Kerr 2008), to visually rate the skin response to aqueous methyl nicotinate (niacin) with respect to both redness and oedema as a function of increasing niacin concentrations.Ratings will be acquired every three minutes over a 12-minute period starting at the time of solution application.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">107</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Caucasian males and females between 19 and 30 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Episode Psychosis</arm_group_label>
    <description>Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin test</intervention_name>
    <description>four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>First Episode Psychosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy young adults
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  caucasian

          -  within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis,
             schizophrenia, schizoaffective disorder or psychotic disorder NOS

          -  outpatient

        Exclusion Criteria:

          -  known allergy to study compound (methyl nicotinate, vitamin B3, niacin)

          -  skin conditions (e.g., dermatitis, psoriasis, eczema)

          -  diagnosis or treatment for medical conditions that may affect normal vascular tone
             (e.g., diabetes, vasculitis, chronic hypertension, etc.)

          -  Use of anti-inflammatory, antibiotic, or antihistamine medications within one month
             prior to study entry

          -  Use of supplements like Omega 3 fatty acids within 3 months prior to study entry

          -  Use of vitamin or nutritional supplement containing a dose of niacin/nicotinic acid
             above 50 mg/day at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip G Tibbo, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Capital District Health Authority, Nova Scotia, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nova Scotia First Episode Psychosis Program; QEII health Sciences Centre; Capital District Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kerr M, Cotton S, Proffitt T, McConchie M, Markulev C, Smesny S, McGorry P, Berger G. The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls. Prostaglandins Leukot Essent Fatty Acids. 2008 Jul-Aug;79(1-2):15-9. doi: 10.1016/j.plefa.2008.06.001. Epub 2008 Jul 24.</citation>
    <PMID>18656334</PMID>
  </reference>
  <reference>
    <citation>Nadalin S, Buretić-Tomljanović A, Rubesa G, Tomljanović D, Gudelj L. Niacin skin flush test: a research tool for studying schizophrenia. Psychiatr Danub. 2010 Mar;22(1):14-27. Review.</citation>
    <PMID>20305586</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Beverly Butler</investigator_full_name>
    <investigator_title>Research Neuropsychologist</investigator_title>
  </responsible_party>
  <keyword>Diagnostic Techniques and Procedures</keyword>
  <keyword>Sensitivity and Specificity</keyword>
  <keyword>Skin Tests</keyword>
  <keyword>Biological Markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

